
Albert Borla
Chairman and CEO of Pfizer discussing the company's pipeline priorities including weight-loss and GLP-1 programs (monthly dosing), acquisitions (Biohaven, Cigen, Metera), loss of exclusivity planning, MFN negotiations, and dividend outlook.



